z.szabo

TL2 Moderator · Nantes

Contributes reviews on supplier material. Based in Nantes.

Joined 28 April 2025 · last posted 8d · groups: translators, regional-na, regional-apac

95Posts here

4Topics

2Solutions

163Likes received

190Likes given

22Badges

113Days visited

1.1kPosts read

Recent activity

Full stream

What is genuinely unknown about long-term amylin agonism Replied, post #59 · Compounds › Cagrilintide & amylin analogues · 20 Jul 2026 · 6 likes Amylin signalling is distinct from GLP-1 signalling. Amylin slows gastric emptying and promotes satiety through a different receptor and different neural pathways. The…
Follow-up: How compounding permissions changed when supply normalised Replied, post #25 · Sourcing › Regulatory · 15 Jul 2026 · 8 likes On post #21 — agreed on the reasoning, with one qualification. Off-label use and medical practice: clinicians can prescribe approved medications off-label under some…
A critique that turned out to be unfair, retracted by its author Replied, post #29 · Evidence › Study critique · 12 Jul 2026 · 5 likes Multiple comparisons: if a paper reports many outcomes, the chance of a spurious association by random chance is real. Pre-specification of primary outcomes matters and…
Why retatrutide discussion here is more cautious than elsewhere — one year on Replied, post #54 · Compounds › Retatrutide · 11 Jul 2026 · 0 likes Why this subcategory is more cautious than elsewhere: retatrutide is investigational, phase 3 is ongoing, and the heart-rate signal in phase 2 is not negligible.…
Why we ask for units every single time, with three examples of what goes wrong Replied, post #113 · Start Here › How to Ask · 9 Jul 2026 · 32 likes post #112 answers the question as asked. The question underneath it is different. Arithmetic questions: write out the steps. "I have a 10 mg vial, I added 2 mL, I want…
Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #55 · Analytics › Impurities & related substances · 7 Jul 2026 · 8 likes Incomplete deprotection: mass higher by the protecting group mass. Usually markedly later eluting. A synthesis artifact from incomplete removal of protecting groups.
Submitting a sample: the process end to end Replied, post #51 · Sourcing › Independent verification · 1 Jul 2026 · 9 likes Blind sampling: submitting without the laboratory or seller knowing the source removes the two easiest ways for a result to be shaped: selective submission and…
Journal club: what we got wrong in an earlier session Replied, post #25 · Evidence › Journal club · 24 Jun 2026 · 3 likes I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The distinction being drawn does not survive when you look at…
Ultrasound and skinfolds: operator dependence in practice Replied, post #19 · Outcomes › Body composition · 16 Jun 2026 · 1 like Precision versus accuracy: the precision you need depends on what question you are answering. "Am I losing fat?" requires less precision than "Is my lean mass…
What steady state means for the decision to escalate Replied, post #12 · Practice › Dosing & titration · 11 Jun 2026 · 1 like Picking up post #9: that is the part I would want checked first. Stepping down deliberately: the withdrawal trials show that stopping is followed by regain. The…
Tracking a shortage from primary sources rather than rumour Replied, post #42 · Access › Shortages · 8 Jun 2026 · 1 like Resuming after a gap: after a gap of days or a few weeks, most people resume at the dose they were on when they stopped. Gaps of months might require retitration…
Electrolyte supplements: which ones do anything Replied, post #25 · Nutrition & Training › Hydration & electrolytes · 7 Jun 2026 · 0 likes Lab testing: if symptoms are severe or persistent, checking electrolytes and minerals (sodium, potassium, magnesium, calcium) and interpreting them in context of losses…